Eden Research Plc · LSE:EDEN

Eden Research — Investor Presentation (February 2025)

13 slides from Eden Research's investor presentation, Feb 13, 2025

  1. Slide 1: Eden Research plc 2025 Investor presentation

    Eden Research plc Eden Research plc is a leader in sustainable biopesticide and biocontrol technology. 2025 Investor presentation February 2025

  2. Slide 2: Executive team

    Executive team 2 Sean Smith Alex Abrey Chief Executive Officer Chief Financial Officer Over 25 years experience in the Experienced Financial Director to a speciality chemicals and industrial diverse range of businesses including biotechnology industries financial and management consultancy ‐ 10+ yea

  3. Slide 3: Company information

    Company information 3 Key statistics Eden is the only UK quoted (AIM: EDEN) company focused on plant-derived biopesticides for sustainable agriculture Regulatory Crop uses Intellectual property and Multiple regulatory expertise in plant-derived clearances (EU, US, AUS, NZ) approvals sustainable chem

  4. Slide 4: Core business, IP & unique selling proposition

    Core business, IP & unique selling proposition 4 Eden’s focus is on developing plant-derived biopesticides using its two proprietary technology platforms: $11bn 36 The global biopesticides Number of pesticides • Plant-derived (terpene) active ingredients market is projected to banned in the EU since

  5. Slide 5: Product development roadmap

    Product development roadmap 5 Late Product Target Crops/markets Discovery Early development development Partnerships Mevalone (fungicide) Botrytis, powdery High-value fruits & mildew, downy vegetables (EU, US, mildew Oceania) Cedroz (nematicide) Nematodes High-value fruits & vegetables (EU) Ecovelex

  6. Slide 6: Revenue potential by product

    Revenue potential by product 6 Total Total EU US (EU/US) (global) • Illustration based upon current €m €m €m £m and in-process labels, but ignoring future expansions of indicated Mevalone (botrytis) 3 3 6 15 uses • Peak sales generally occur 3 years Mevalone (downy mildew) 8* - 8 38 from the launch

  7. Slide 7: Key partners

    Key partners 7 Corteva Agriscience is a publicly traded agricultural company that produces seeds, crop protection products, and digital services. The company was formed in 2019 when DuPont Crop Protection, DuPont Pioneer, and Dow AgroSciences merged and in 2023 had revenue of $17bn. Established in 1

  8. Slide 8: Market Adoption and Regulatory Overview

    8 Market Adoption and Regulatory Overview Why do farmers use Eden’s products? ‐ Mevalone, Cedroz and Ecovelex are all proven products ‐ They are: ‐ are a reliable alternative to conventional control ‐ provide phased release for prolonged effects ‐ are easy to use and apply ‐ provide improved stabili

  9. Slide 9: Financials

    Financials 10 • Significant increase in revenue: 2025 2024 2023 2022 • 34% vs 2023 forecast unaudited YOY % • Significant increase in product sales: £m £m £m £m change • 38% vs 2023 Revenue 5.0 4.3 34 3.2 1.8 • Strong financial position: Product sales 4.6 3.6 38 2.6 1.7 • Cash at bank at 31 December

  10. Slide 10: Institutional and Directors' Shareholdings

    Institutional and Directors’ Shareholdings 11 % of the issued ordinary Share purchases Shareholder Number of shares share capital Jan/Feb 2025 Gresham House Asset Management Limited 52,882,786 9.92% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Man

  11. Slide 11: Case Study: Ecovelex Bird repellent seed treatment

    Case Study: Ecovelex 12 Bird repellent seed treatment Background Current status Ecovelex has been sold in Italy in the Ecovelex is a biological bird repellent seed Semi-field studies showed past two years under emergency use treatment initially for use on maize. good efficacy authorisation Two incum

  12. Slide 12: Investment summary

    Investment summary 13 01 Commercialisation Eden is well-placed to further commercialise multiple products in order to 05 Increase number of commercial partners Opportunity to increase the number accelerate growth of commercial partners and diversify product range 02 Technology exploitation Ability t

  13. Slide 13: Thank you

    THANK YOU CONTACT: INFO@EDENRESEARCH.COM LSE: EDEN.L

Eden Research — Investor Presentation (February 2025) on 6ix